Cytokinetics (CYTK) Director James Daly Files Form 3, Reports Zero Beneficial Ownership

Rhea-AI Filing Summary

CYTK Form 3 — initial statement by Director James M. Daly This filing reports that James M. Daly, listed as a director of Cytokinetics, Inc., filed an initial Form 3 dated 08/19/2025 and reports no securities beneficially owned in the issuer. The form was signed by an attorney-in-fact on Mr. Daly’s behalf.

Insights

Financial Analyst

TL;DR: Routine disclosure; director reports no holdings, so no direct equity signal to investors.

The Form 3 is an initial Section 16 filing showing James M. Daly as a director with no beneficial ownership of Cytokinetics securities as of the 08/19/2025 event date. For market impact, absence of holdings from a director is typically neutral and provides no immediate information about insider buying or selling. This is a routine compliance disclosure rather than a material corporate event.

Corporate Governance Expert

TL;DR: Governance disclosure completed; lack of reported ownership limits insider alignment signals.

The filing fulfills the initial reporting obligation under Section 16 for a director. It explicitly states "No securities are beneficially owned," which is a factual compliance statement. From a governance perspective, the absence of reported holdings means there is no insider ownership disclosed to assess alignment with shareholders; however, the filing itself is a standard procedural document.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Daly James M

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94580

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/19/2025

3. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Daly	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the CYTK Form 3 filed by James M. Daly report?

The Form 3 reports that James M. Daly, a director of Cytokinetics (CYTK), beneficially owns no securities in the issuer as of 08/19/2025.

When was the event date reported on the Form 3 for CYTK?

The date of the event requiring the statement is 08/19/2025.

Who signed the Form 3 filed for James M. Daly?

The form was signed by John O. Faurescu as attorney-in-fact for Mr. Daly on 08/19/2025.

Does this Form 3 indicate any derivative or non-derivative holdings for CYTK?

No. The filing explicitly states "No securities are beneficially owned," so there are no listed non-derivative or derivative holdings.

Is the CYTK Form 3 considered a material event for investors?

According to the filing content, this is a routine initial disclosure and does not, by itself, indicate a material change to the company’s operations or finances.